Santiago Escrivá de Romaní is a Medical Oncologist who belongs to the Breast Cancer Unit in Vall d’Hebron Institut of Oncology (VHIO) and Hospital Vall d’Hebron in Barcelona, Spain. He is an attending physician and clinical investigator with a main focus and interest in HER2-positive breast cancer and in the development of new treatments and therapeutic strategies.

Dr Santiago Escrivá de Romaní has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca/Daiichi Sankio, Eisai, Kern, Pfizer, Roche, Seagen and Zymeworks.